COMMUNIQUÉS West-GlobeNewswire
-
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
14/05/2026 -
CJ Biomaterials Launches New Home Compostable all-PHA Extrusion Coating Resin for Paper Food Serviceware
14/05/2026 -
Easy Environmental Solutions & Terreplenish® Show Outstanding Yield Increases & Offer Alternative To Petroleum-Based Fertilizers
14/05/2026 -
Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026
14/05/2026 -
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026 -
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
14/05/2026 -
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
14/05/2026 -
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026 -
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
14/05/2026 -
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14/05/2026 -
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
14/05/2026 -
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
14/05/2026 -
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
14/05/2026 -
Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
14/05/2026 -
CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
14/05/2026 -
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
14/05/2026 -
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
14/05/2026 -
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026 -
Biogen Completes Acquisition of Apellis Pharmaceuticals
14/05/2026
Pages